阿那莫林治疗癌症恶病质的禁忌有哪些?

Author: Medicalhalo

Release time: 2025-10-19 11:44:20

The contraindications of anamorelin in the treatment of cancer cachexia are as follows:

1. Patients with severe liver damage should not use anamorelin. The liver plays an important role in drug metabolism, and impaired liver function may affect the normal metabolism of drugs, thereby increasing the risk of adverse reactions.

2. Patients who are allergic to anamulin or its components should avoid using this drug. Anaphylaxis may include symptoms such as rash, hives, shortness of breath, and in severe cases may even lead to anaphylactic shock.

3. Patients with serious heart problems, such as heart failure, myocardial infarction, etc., should avoid using anamorelin. This is because the drug may aggravate heart conditions, leading to more serious consequences.

4. Patients who are taking one of the following drugs:

Itraconazole, nelfonavir, nelfinavir, clarithromycin, innavir, sakinavir, morinda officinale, boriconazole, indigomycin, tiplaprovir, ritonavir-containing preparations, and comvitatide-containing preparations.

5. Patients who have difficulty in taking food orally due to organic abnormalities of the digestive tract such as digestive tract occlusion.

Anamulin Precautions

1. Before and during administration, pulse, blood pressure, cardiothoracic ratio, electrocardiogram, electrolytes, etc. should be measured regularly. If abnormalities are found, administration should be stopped.

2. Blood glucose and urine glucose should be measured regularly before and during administration.

3. For pregnant women or women who may be pregnant, only administer the drug when the benefits of treatment are judged to outweigh the risks.

4. Use with caution during lactation. It is not clear whether this agent is transferred to breast milk.

About Anamorelin

Anamorelin is a non-peptide, orally active, centrally penetrating, selective agonist that promotes the production of ghrelin/growth hormone secretagogue receptors and has appetite-promoting and anabolic effects. Anamorelin significantly increased appetite, overall body weight, lean body mass, and muscle strength.

Effectiveness of Anamorelin Treatment

A multicenter, open-label, single-arm study included Japanese patients with non-small cell lung cancer or gastrointestinal cancer with cancer cachexia (body mass index <20 kg/m2 involuntary weight loss within the past 6 months> 2% and anorexia).

Test method

Patients took 100 mg once a day for 24 weeks. The primary endpoint was composite clinical response (CCR) at 9 weeks, defined as a ≥5% increase in body weight from baseline, a ≥2-point increase in the 5-item Anorexia Symptom Scale score on the Anorexia/Cachexia Treatment Functional Assessment, and survival.

Trial results

102 patients met the criteria and were included in the study. The mean and standard deviation of age and body mass index were 71.0±8.2 years and 17.47±1.48 kg/m2, respectively. The CCR rate at 9 weeks was 25.9%, meeting the primary endpoint, and the lower 95% CI exceeded the prespecified minimum of 8%.

Improvements in weight and anorexia are long-lasting and are accompanied by an improvement in the patient's overall impression of changes in appetite/eating-related symptoms and overall condition.

Trial safety

Adverse drug reactions occurred in 37 of 101 treated patients (36.6%), the most common being increased glycosylated hemoglobin, constipation and peripheral edema.

For more information about the safety of anamulin, please click: This article has a detailed introduction.

Trial Conclusion

Anamulin improves body weight and anorexia-related symptoms in patients with cancer cachexia and low body mass index, with durable efficacy and good safety and tolerability.

Menu